Abstract:Background: The treatment of recurrent glioblastoma faces many challenges. The development of new therapeutic approaches and the exploration of biomarkers of therapeutic effectiveness will provide a basis for better tumor control and individualized diagnosis and treatment. TTFields therapy, bevacizumab and second-line chemotherapy are the alternative treatment methods for recurrent gliomas. Especially, the introduction of TTFields has prolonged the tumor control of patients. Clinical studies have shown that bevacizumab combined with chemotherapy can improve the prognosis of patients. In this study, the randomized controlled principle was used to compare TTFields plus second-line chemotherapy and combined chemotherapy on the basis of both, and to explore the safety and effectiveness of combined treatment for patients with recurrent glioblastoma. Objectives: 1. To evaluate the safety and efficacy of TTFields, bevacizumab, and second-line chemotherapy in the treatment of relapsed GBM. 2. To evaluate the effects of TTFields, bevacizumab and their combination on the permeability of the blood-brain barrier. 3. To explore the correlation between serum VEGF, plasma MMP-2, MMP-3 and other factors and the efficacy of combination therapy. Methods: A total of 40 patients who met the inclusion criteria were planned to be recruited and randomly assigned to two experimental groups, with 20 patients in each group. On the basis of second-line chemotherapy, patients in each group were treated with TTFields alone, TTFields combined with BEV, respectively. The 6-month survival rate was used as the primary outcome, and the median OS and median PFS were used as the secondary outcomes. The effectiveness and safety of each regimen was evaluated and compared. Krans, CBV, CBF, MTT and other imaging indicators were used to evaluate vascular permeability and blood flow. To compare the differences between BEV alone and BEV combined with TTFields, and to evaluate the efficacy prediction of these hematologic molecules in the combined regimen. Moreover, imaging and hematological indicators were combined to construct a prognostic model that could predict the efficacy of the combined regimen. Key Issues to be Resolved: 1. To evaluate the comprehensive effect of TTFields combined with BEV treatment on blood-brain barrier permeability and blood perfusion. 2. A prognostic prediction model will be established by combining imaging features and hematological indicators. 3. Preliminarily determine the direction of optimization of the combined treatment program. Citation Format: Xun Kang, Zehao Cai, Feng Chen, Botao Zhang, Bo Jiang, Wenbin Li. Safety and efficacy of Tumor Treating Fields (TTFields) combined with bevacizumab and systemic chemotherapy in recurrent GBM [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl) nr CT113.

Effect of bevacizumab in treatment of children with optic pathway glioma

Inhibitory Effect of Carboplatin in Combination with Bevacizumab on Human Retinoblastoma in an in Vitro and in Vivo Model

Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.

Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components

Efficacy and Safety of Bevacizumab Combined with Temozolomide in the Treatment of Glioma: A Systematic Review and Meta-Analysis of Clinical Trials

Efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced colorectal cancer and the effect on its adverse reactions

Effect of bevacizumab combined with chemotherapy at different sequences in the gastric-cancer-bearing nude mice

A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.

Safety and Efficacy of Bevacizumab Combined with R-CHOP Regimen in Seven Chinese Patients with Untreated Diffuse Large B-cell Lymphoma

The efficacy and adverse events of bevacizumab combined with temozolomide in the treatment of glioma: a systemic review and meta-analysis of randomized controlled trials

[Efficacy of Intravitreal Carboplatin Plus Bevacizumab in Refractory Retinoblastoma].

Efficacy and safety of bevacizumab combined with chemotherapy in HER2 negative advanced breast cancer

Bevacizumab in combination with various chemotherapy protocols for treatment of advanced colorectal cancer:a clinical evaluation

Research Progress on the Mechanisms of Combined Bevacizumab and Radiotherapy

Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

A Systematic Review and Meta-Analysis on the Effectiveness of Radiotherapy and Temozolomide Treatment With or Without Bevacizumab in Patients With Glioblastoma Multiforme

The Optimal Timing And Courses Of Bevacizumab Added To Chemotherapy For Non-Squamous Non-Small Cell Lung Cancer: Revelations From The Real-World Experience In A Single Chinese Cancer Center

Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study

Abstract CT113: Safety and efficacy of Tumor Treating Fields (TTFields) combined with bevacizumab and systemic chemotherapy in recurrent GBM

Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial